Nilotinib is designed based on the structure of IM and shows higher affinity to the ATP-binding site of ABL kinase to overcome IM-resistant chronic myeloid leukemia (CML) and also selectively inhibits KIT and PDGFR [10]. Here, PDGFRB is linked to chronic myelogenous leukemia, BCR-ABL1 positive.